2015 Drug Recalls: While FDA Drove Pharmacies, Quality Systems Drove Manufacturers
This article was originally published in The Gold Sheet
Huge recall numbers last year reflected FDA's continued enforcement of sterility assurance at compounding pharmacies, while generic and brand manufacturers dealt with particulate contamination and various out-of-specification issues.
You may also be interested in...
Data integrity warning letter to Chinese API maker reflects continuing focus of FDA enforcement efforts on the pharmaceutical industry's Asian supply chain.
How contamination, sterility assurance, OOS and other issues caused drug recalls to spike again last year. What happened at Aidapak, H&P, Ben Venue, Hospira, Teva and other manufacturers to set a new record.
Driven by COVID-19 pandemic challenges, regulatory authorities from multiple regions want to work with sponsors on new joint approaches for expediting manufacturing changes globally and streamlining preapproval and pre-licensing inspections.